Mostrando 10 resultados de: 17
Filtros aplicados
Subtipo de publicación
Article(17)
Publisher
BMC Cancer(1)
BMC Infectious Diseases(1)
BMC Pharmacology and Toxicology(1)
Biopharmaceutics and Drug Disposition(1)
Biotecnologia Aplicada(1)
Área temáticas
Enfermedades(14)
Farmacología y terapéutica(11)
Medicina y salud(4)
Microorganismos, hongos y algas(3)
Bioquímica(2)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(17)
ODS 10: Reducción de las desigualdades(16)
ODS 17: Alianzas para lograr los objetivos(8)
ODS 9: Industria, innovación e infraestructura(4)
ODS 5: Igualdad de género(2)
Origen
google(7)
Comparative Neuroregenerative Effects of C-Phycocyanin and IFN-Beta in a Model of Multiple Sclerosis in Mice
ArticleAbstract: Multiple Sclerosis (MS) therapies approved so far are unable to effectively reverse the chronic phasPalabras claves:C-Phycocyanin, EAE, IFN-beta, Multiple Sclerosis, Neuroregeneration, RemyelinationAutores:Alexey Llópiz-Arzuaga, Bergami A., Fernández-Massó J.R., Furlan R., Herrera-Rolo T., Lagumersindez-Denis N., Marín-Prida J., Muzio L., Nazabal-Galvez M., Pentón-Arias E., Pentón-Rol G., Polentarutti N., Raíces-Cruz I., Teixeira M.M., Valenzuela-Silva C.M., Veliz-Rodriguez T.Fuentes:googlescopusC-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells
ArticleAbstract: For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerPalabras claves:Central nervous system, Demyelination, Multiple Sclerosis, Neurodegenerative disorder, Regulatory T cellsAutores:Acosta-Medina E.F., Alexey Llópiz-Arzuaga, Alonso-Ramírez R., Cervantes-Llanos M., Falcón-Cama V., Guillén-Nieto G.E., Lagumersindez-Denis N., López-Saura P.A., Marín-Prida J., Martínez-Sánchez G., Pentón-Arias E., Pentón-Rol G., Rodríguez-Jiménez E., Valenzuela-Silva C.M.Fuentes:googlescopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusCIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
ArticleAbstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, wPalabras claves:apoptosis, Cancer targeted therapy, Casein kinase 2Autores:Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.Fuentes:googlescopusAdjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study
ArticleAbstract: Background: High antibiotic resistance is described in atypical Mycobacteriosis, mainly by MycobactePalabras claves:Autores:Bello-Rivero I., Fernández-Olivera N., García-García I., González-Méndez L., Jiménez-Madrigal G., López-Saura P.A., Martínez-Sánchez G., Milanés-Virelles M.T., Rodríguez-Acosta C., Sánchez-de la Osa R.B., Santos-Herrera Y., Thelvia I. Ramos Gómez, Valdés-Quintana M., Valenzuela-Silva C.M.Fuentes:googlescopusErythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study
ArticleAbstract: Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) anPalabras claves:Clinical trial, erythropoietin, human-recombinant erythropoietin, spinocerebellar ataxia type 2Autores:Almaguer Gotay D., Amaro-González D., Aymed-García J., Batista-Nuñez M., Canales-Ochoa N., Carmen Elena Viada, Columbié Ximelis J., Crombet-Ramos T., Estupiñán Rodriguez A., García-García I., García-Rodriguez J.C., Hernández Casaña P., Jiménez-Rodríguez D., Labrada Aguilera P.E., Medrano Montero J., Ortega-Sanchez R., Padrón-Estupiñan M.d.C., Peña Acosta A., Rodríguez-Labrada R., Rodriguez-Obaya T., Santos-Morales O., Silva Ricardo Y., Torres Vega R., Tribin Rivero K., Valenzuela-Silva C.M., Valle Cabrera R., Vazquez-Mojena Y., Velazquez-Perez L.Fuentes:scopusIntegrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody
ArticleAbstract: The multiple-dose strategy with the monoclonal ior EGF/r3 antibody, in xenograft bearing nude mice,Palabras claves:Allometric scaling, Dosage regimen, Integrated pharmacokinetic-pharmacodynamic, Monoclonal antibody ior EGF/r3, Survival time, Tumor growth delayAutores:Alonso K., Alvarez D., Beausoleil I., Bécquer M.d.l.A., Castillo R., Duconge J., Fernández-Sánchez E.M., Matheu J., Tania Crombet, Valenzuela-Silva C.M., Vecino G.Fuentes:scopusRecombinant gamma interferon for the treatment of pulmonary and mycobacterial diseases
ArticleAbstract: An increased antibiotic resistance is described for Mycobacterium tuberculosis and atypical mycobactPalabras claves:BCG, Idiopathic pulmonary fibrosis, Interferon gamma, Lymphadenitis, Multidrug-resistant pulmonary tuberculosis, Mycobacteria, Mycobacterium avium complexAutores:Abreu G., Cayón I., García I., González-Méndez L., Jiménez G., López P., Milanés M.T., Sánchez R.B., Santos Y., Thelvia I. Ramos Gómez, Valdés M., Valenzuela-Silva C.M.Fuentes:googlescopusSafety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
ArticleAbstract: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoiPalabras claves:Conjugate-vaccine, COVID-19 Vaccine, Heterologous scheme, RBD-subunit vaccine, SARS-COV-2, Vaccine efficacyAutores:Bacallao-Castillo J.P., Baldoquín-Rodríguez W., Biglari A., Caballero-González E., Climent-Ruiz Y., Doroud D., Duartes-González R., Egües-Torres L., Fernández-Castillo S., Fonte-Galindo O., García-Blanco S., García-Carmenate M., García-Rivera D., González-Mujica Romero R., Gouya M.M., Herrera-Marrero N., Huete-Ferreira S., Idalmis-Cisnero K., Licea-Martín E., Martínez-Pérez M., Meliá-Pérez D., Mendoza-Hernández I., Misladys Rodríguez Ortega, Paredes-Moreno B., Pérez-Cabrera S., Rodríguez-González M., Rojas-Remedios I., Samón-Tabio O., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Van Der Stuyft P., Velazco-Villares P., Verez-Bencomo V.Fuentes:scopusPharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
ArticleAbstract: Background: More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. TPalabras claves:2'-5' oligoadenylate synthetase, Beta2-microglobulin, interferons, Neopterin, pharmacodynamics, pharmacokineticsAutores:Bello-Rivero I., Campos-Mojena R., Cruz-Ramírez A., Díaz-Machado A., García-Vega Y., González-Delgado C.A., Hernández-González I., I. Howland-Álvarez, López-Saura P.A., Martín-Trujillo A., Pérez-Rodríguez S., Santana-Milián H., Tuero-Iglesias Á.D., Valenzuela-Silva C.M.Fuentes:scopus